An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature.
Overexpression of the adverse prognostic marker ERBB2 occurs in 30% of breast cancers; however, therapies targeting this gene have not proved to be as effective as was initially hoped. Transcriptional profiling meta-analyses have shown that there are approximately 150 genes co-overexpressed with ERBB2, suggesting that these genes may represent alternative factors influencing ERBB2-positive tumors. Here we describe an RNA interference-based analysis of these genes that identifies transcriptional regulators of fat synthesis and storage as being critical for the survival of these cells. These transcription factors, nuclear receptor subfamily 1, group D, member 1 (NR1D1) and peroxisome proliferator activated receptor gamma binding protein (PBP), both reside on ERBB2-containing 17q12-21 amplicons and are part of the ERBB2 expression signature. We show that NR1D1 and PBP act through a common pathway in upregulating several genes in the de novo fatty acid synthesis network, which is highly active in ERBB2-positive breast cancer cells. Malate dehydrogenase 1 and malic enzyme 1, enzymes that link glycolysis and fatty acid synthesis, are also regulated by NR1D1. The resulting high-level fat production from increased expression of these genes likely contributes to an abnormal cellular energy metabolism based on aerobic glycolysis. Together, these results show that the cells of this aggressive form of breast cancer are genetically preprogrammed to depend on NR1D1 and PBP for the energy production necessary for survival.
Department of Biomedical Sciences, Cancer Research Center, University at Albany, Rensselaer, New York 12144-3456, USA.
Antonis
A
Kourtidis
Ritu
R
Jain
Richard D
RD
Carkner
Cheryl
C
Eifert
M Julia
MJ
Brosnan
Douglas S
DS
Conklin
D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D005227:Fatty Acids / Q000096:biosynthesis; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D050356:Lipid Metabolism / Q000235:genetics; D056913:Mediator Complex Subunit 1 / Q000235:genetics* / Q000378:metabolism; D056953:Nuclear Receptor Subfamily 1, Group D, Member 1 / Q000235:genetics* / Q000378:metabolism; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics; D014162:Transfection
D005227:Fatty Acids; D056913:Mediator Complex Subunit 1; D056953:Nuclear Receptor Subfamily 1, Group D, Member 1; D034741:RNA, Small Interfering; D018719:Erb-b2 Receptor Tyrosine Kinases; C064353:NR1D1 protein, human